Page last updated: 2024-10-27

gabexate and Epidermolysis Bullosa

gabexate has been researched along with Epidermolysis Bullosa in 2 studies

Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.

Epidermolysis Bullosa: Group of genetically determined disorders characterized by the blistering of skin and mucosae. There are four major forms: acquired, simple, junctional, and dystrophic. Each of the latter three has several varieties.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kaneko, F1
Tsukinaga, I1
Ando, M1
Ohkawara, A1
Oguchi, H1
Oikawa, K1
Nagai, M1
Ikeda, S1
Manabe, M1
Muramatsu, T1
Takamori, K1
Ogawa, H1

Other Studies

2 other studies available for gabexate and Epidermolysis Bullosa

ArticleYear
Studies on two siblings with recessive dystrophic epidermolysis bullosa (Hallopeau-Siemens) and the plasminogen activator and its inhibitor in the lesion.
    Dermatologica, 1989, Volume: 178, Issue:3

    Topics: Adolescent; Child; Epidermolysis Bullosa; Esters; Female; Gabexate; Genes, Recessive; Guanidines; HL

1989
Protease inhibitor therapy for recessive dystrophic epidermolysis bullosa. In vitro effect and clinical trial with camostat mesylate.
    Journal of the American Academy of Dermatology, 1988, Volume: 18, Issue:6

    Topics: Administration, Topical; Adolescent; Adult; Blister; Child; Epidermolysis Bullosa; Esters; Female; G

1988